Advances in Cancer Drug Targets is an e-book series that brings together recent expert reviews published on the subject with a focus on strategies for synthesizing and isolating organic compounds and elucidating the structure and nature of DNA. The reviews presented in this series are written by experts in pharmaceutical sciences and molecular biology. These reviews have been carefully selected to present development of new approaches to anti-cancer therapy and anti-cancer drug development. The contents of this volume include reviews on mediating or inhibiting different signaling pathways such as WNT signaling and MTOR as well as novel drug targets for tumor control such as neutrophil elastase and estrogen sulfatase. These reviews provide updates on new ways to treat a variety of cancers. The reference work serves to give readers a brief yet comprehensive glance at current theory and practice behind employing chemical compounds for tackling tumor suppression, DNA site specific drug targeting and the inhibition of enzymes involved in growth control pathways. This e-book volume will be of special interest to molecular biologists and pharmaceutical scientists.

Nanomedicine is a rapidly expanding field because of its benefits over conventional drug delivery technology, as it offers site-specific and target-oriented delivery of therapeutic agents. Nanoparticles and Nanocarriers Based Pharmaceutical Preparation presents a structured summary of recent advances and discoveries in nanomedicine and nanocarrier-based drug delivery. The book covers several key topics in a very simple and easy to understand language. Readers will be familiarized with many types of nanocarriers that have been developed over the past decade, the pharmaceutical formulations composed of organic and inorganic materials as well as their clinical benefits. Chapters are written with the help of authoritative sources of knowledge with the goal of building a foundational understanding of novel drug delivery systems. Since the subject matter is interdisciplinary, it will be of interest to students, teachers and researchers in a broad range of fields, including pharmaceutical sciences, nanotechnology, biomedical engineering and material sciences.

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. Onset of obesity in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is focused on this very important area of healthcare research. Fifteen well written reviews make this special volume an excellent compilation of recent developments in anti-obesity treatment. The reviews cover a variety of topics including the development of specific, safe and effective receptor antagonists, the role of epithelial endocrine cells and post operative treatment strategies. This book should be useful to clinicians and medicinal chemists involved in ant-obesity research and therapy.

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. Onset of obesity in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is focused on this very important area of healthcare research. Fifteen well written reviews make this special volume an excellent compilation of recent developments in anti-obesity treatment. The reviews cover a variety of topics including the development of specific, safe and effective receptor antagonists, the role of epithelial endocrine cells and post operative treatment strategies. This book should be useful to clinicians and medicinal chemists involved in ant-obesity research and therapy.

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. Onset of obesity in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is focused on this very important area of healthcare research. The third volume of this series is dedicated to anti-obesity treatments including updates on new therapeutics for obesity, Nesfatin-1 and its therapeutic uses, the role of proteomics in pediatric anti-obesity treatment, the role of oxidative stress in childhood obesity and a review of data on gut microbiota as a treatment option for obesity.

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. The incidence of obesity among populations in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from activities focused on raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is a book series focused on this very important area of healthcare research. Each volume presents insightful updates on pharmaceutical research and development for clinical researchers and healthcare professionals involved in obesity treatment programs.</p> <p> The fourth volume of this series covers 6 reviews on anti-obesity treatment strategies including updates on obesity and cancer prevention through dietary modulation, the role of anti-obesity medications in polycystic ovary syndrome, potential anti-obesity strategies targeting mitochondria, calcium silicate based formulations for anti-obesity therapy, and the identification of obesity medications from natural products and plants.</p>

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. The incidence of obesity among populations in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from activities focused on raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is a book series focused on this very important area of healthcare research. Each volume presents insightful updates on pharmaceutical research and development for clinical researchers and healthcare professionals involved in obesity treatment programs. The fifth volume of this series is a compilation of 6 reviews of interesting topics on the subject that highlight different aspects of obesity treatment and management, some of which are novel approaches. Topics covered in this volume include: - the effect of sleep on weight and obesity management - AMPK as a postulated target for metabolic syndrome and obesity - Harnessing addiction neuroscience to treat obesity - Current treatment of obesity versus the next generation of anti-obesogenic drugs: an ecologically and sustainable approach to health - Leptin and leptin sensitizers for the treatment of obesity related conditions - MicroRNAs as targets for the management of obesity

Animal models of diseases play a pivotal role in drug discovery and development, not only for proof of the concept studies of efficacy, PK/PD relationship but also for drug safety assessment. Since considerable differences in variables exist between animal models and human models (such as genetics, physiology, anatomy, gene expression, heterogeneity of disease conditions, etc.), not all the preclinical models are able to represent the pathophysiological conditions in human diseases. Therefore, partly due to the lack of congruency between animal and human disease models, several proposed therapeutic agents in the past decades have been demonstrated to be effective in preclinical models but failed in clinical studies. This e-book focuses on animal models of diseases from a translational perspective and highlights the key advantages and limitations of each model described to facilitate drug discovery and development. A unique feature of the volume is that it contains a selection of details disease models in various therapeutic niches with significant unmet medical needs, including inflammation, neurological diseases, cardiovascular and metabolic diseases, and oncology. This e-book is, therefore, of considerable value to researchers and clinicians involved in drug discovery and development as well as pathology.